Although GeoVax is currently being tested clinically for HIV prevention, this is the first clinical trial in which the same products are being used for treatment of persons who already have HIV infection.
UAB joins the AIDS Research Consortium of Atlanta (ARCA) as the second site used for this trial.
The study will enroll 10 to 12 patients, who have been diagnosed within the first year of HIV infection and have started antiretroviral drug therapy within six months of diagnosis.
The study will last up to 77 weeks for each participant, and all patients would be followed closely to assess vaccine safety and for the ability of the vaccine to induce therapeutic immune responses.